BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8635381)

  • 1. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy.
    Knight SB; Delbeke D; Stewart JR; Sandler MP
    Chest; 1996 Apr; 109(4):982-8. PubMed ID: 8635381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.
    Patz EF; Lowe VJ; Hoffman JM; Paine SS; Burrowes P; Coleman RE; Goodman PC
    Radiology; 1993 Aug; 188(2):487-90. PubMed ID: 8327702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating benign and malignant pulmonary lesions with FDG-PET.
    Yang SN; Liang JA; Lin FJ; Kwan AS; Kao CH; Shen YY
    Anticancer Res; 2001; 21(6A):4153-7. PubMed ID: 11911310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis.
    Dewan NA; Reeb SD; Gupta NC; Gobar LS; Scott WJ
    Chest; 1995 Aug; 108(2):441-6. PubMed ID: 7634881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy.
    Lowe VJ; DeLong DM; Hoffman JM; Coleman RE
    J Nucl Med; 1995 May; 36(5):883-7. PubMed ID: 7738668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET.
    Núñez R; Kalapparambath A; Varela J
    Rev Esp Med Nucl; 2007; 26(4):196-207. PubMed ID: 17662186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
    Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
    Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.
    Lowe VJ; Hoffman JM; DeLong DM; Patz EF; Coleman RE
    J Nucl Med; 1994 Nov; 35(11):1771-6. PubMed ID: 7965154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions.
    Imdahl A; Jenkner S; Brink I; Nitzsche E; Stoelben E; Moser E; Hasse J
    Eur J Cardiothorac Surg; 2001 Aug; 20(2):324-9. PubMed ID: 11463551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management.
    Dewan NA; Gupta NC; Redepenning LS; Phalen JJ; Frick MP
    Chest; 1993 Oct; 104(4):997-1002. PubMed ID: 8404239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of radiographically indeterminate solitary pulmonary nodules with.
    Hung GU; Shiau YC; Tsai SC; Ho YJ; Kao CH; Yen RF
    Jpn J Clin Oncol; 2001 Feb; 31(2):51-4. PubMed ID: 11302341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5.
    Chen CJ; Lee BF; Yao WJ; Cheng L; Wu PS; Chu CL; Chiu NT
    AJR Am J Roentgenol; 2008 Aug; 191(2):475-9. PubMed ID: 18647920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.
    Gupta N; Gill H; Graeber G; Bishop H; Hurst J; Stephens T
    Chest; 1998 Oct; 114(4):1105-11. PubMed ID: 9792584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET.
    Gupta NC; Maloof J; Gunel E
    J Nucl Med; 1996 Jun; 37(6):943-8. PubMed ID: 8683316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.
    Deppen S; Putnam JB; Andrade G; Speroff T; Nesbitt JC; Lambright ES; Massion PP; Walker R; Grogan EL
    Ann Thorac Surg; 2011 Aug; 92(2):428-32; discussion 433. PubMed ID: 21592456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Positron emission tomography using 18-FDG-PET in radiologically indeterminate pulmonary lesions].
    Ruiz-Hernández G; de Juan R; Samanes A; Verea H; Peñas JM; Veres A; Lapeña L; Montz R; Carreras JL
    An Med Interna; 2004 Jan; 21(1):12-6. PubMed ID: 15195479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET.
    Hsu WH; Hsu NY; Shen YY; Yen RF; Kao CH
    Cancer Invest; 2003; 21(1):47-52. PubMed ID: 12643009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.